Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses

Author:

White Judith M.12ORCID,Schiffer Joshua T.34,Bender Ignacio Rachel A.34,Xu Shuang4,Kainov Denis567,Ianevski Aleksandr57,Aittokallio Tero789ORCID,Frieman Matthew10ORCID,Olinger Gene G.11,Polyak Stephen J.121314ORCID

Affiliation:

1. University of Virginia, Department of Cell Biology, Charlottesville, Virginia, USA

2. University of Virginia, Department of Microbiology, Charlottesville, Virginia, USA

3. University of Washington, Division of Allergy and Infectious Diseases, Seattle, Washington, USA

4. Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, Washington, USA

5. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

6. Institute of Technology, University of Tartu, Tartu, Estonia

7. Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland

8. Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Oslo, Norway

9. Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

10. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA

11. MRIGlobal, Gaithersburg, Maryland, USA

12. Virology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA

13. Department of Global Health, University of Washington, Seattle, Washington, USA

14. Department of Microbiology, University of Washington, Seattle, Washington, USA

Abstract

The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-equipped for future pandemics. While unprecedented strides have been made developing vaccines and treatments for COVID-19, there remains a need for highly effective and widely available regimens for ambulatory use for novel coronaviruses and other viral pathogens.

Funder

HHS | National Institutes of Health

Ministry of Education and Research | Estonian Research Competency Council

Sigrid Juséliuksen Säätiö

Washington Research Foundation

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3